Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares. Patients and methods [HCQ] was measured in 573 patients with SLE (stable disease and SELENA-SLEDAI≤12) treated with HCQ for at least 6 months. Patients with [HCQ] from 100 to 750 ng/ml were randomised to one of two treatment groups: no daily dose change (group 1) or increased HCQ dose to achieve the target [HCQ] (group 2). The primary end point was the number of patients with flares during 7 months of follow-up. Results Overall, mean [HCQ] was 918±451 ng/ml. Active SLE was less prevalent in patients with higher [HCQ]. A total of 171 patients were randomised and followed for 7 months. SLE flare rates were similar in the two groups (25% in group 1 vs 27.6% in group 2; p=0.7), but a significant spontaneous increase in [HCQ] in both groups between inclusion and randomisation strongly suggested improved treatment adherence. Patients at the therapeutic target throughout follow-up tended to have fewer flares than those with low [HCQ] (20.5% vs 35.1%, p=0.12). Conclusions Although low [HCQ] is associated with higher SLE activity, adapting the HCQ dose did not reduce SLE flares over a 7-month follow-up. ClinicalTrials.gov NCT00413361
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Comparison of drug adherence rates among patients with seven different medical conditions
Briesacher, B. A., Andrade, S. E., Fouayzi, H., & Chan, K. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.437 · Cited by 587
Rand, J. H., Wu, X.-X., Quinn, A. S., Ashton, A. W., Chen, P. P., Hathcock, J. J., Andree, H. A. M., & Taatjes, D. J. (2010) · Blood · doi:10.1182/blood-2009-04-213520 · Cited by 253
Cited by
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
Hydroxychloroquine retinopathy
Yusuf, I. H., Sharma, S., Luqmani, R., & Downes, S. M. (2017) · Eye · doi:10.1038/eye.2016.298 · Cited by 271
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
“In a clinical trial, patients with higher blood levels of HCQ (≥1000 ng/ml) were reported to be less likely to develop active SLE.(351) Nevertheless, both EULAR and American Academy of Ophthalmology recommend that the daily dose of HCQ should not exceed 5mg/kg actual body weight.”
BackgroundImmunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
Carlsson, H., Hjorton, K., Abujrais, S., Rönnblom, L., Åkerfeldt, T., & Kultima, K. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02211-1 · Cited by 48
Metadata
- Authors
- Costedoat-Chalumeau, N., Galicier, L., Aumaître, O., Francès, C., Le Guern, V., Lioté, F., Smail, A., Limal, N., Perard, L., Desmurs-Clavel, H., Boutin, D. L. T. H., Asli, B., Kahn, J.-E., Pourrat, J., Sailler, L., Ackermann, F., Papo, T., Sacré, K., Fain, O., Stirnemann, J., Cacoub, P., Jallouli, M., Leroux, G., Cohen-Bittan, J., Tanguy, M.-L., Hulot, J.-S., Lechat, P., Musset, L., Amoura, Z., Piette, J.-C., Astudillo, L., Belizna, C., Belmatoug, N., Benveniste, O., Benyamine, A., Bezanahary, H., Blanco, P., Bletry, O., Bodaghi, B., Bourgeois, P., Brihaye, B., Chatelus, E., Damade, R., Daugas, E., de-Gennes, C., Delfraissy, J.-F., Delluc, C., Delluc, A., Duhaut, P., Dupuy, A., Durieu, I., Hang-Korng, E., Farge, D., Funck-Brentano, C., Gandjbakhch, F., Gellen-Dautremer, J., Ghillani-Dalbin, P., Godeau, B., Goujard, C., Grandpeix, C., Grange, C., Grimaldi, L., Guettrot-Imbert, G., Guillevin, L., Hachulla, E., Harle, J.-R., Haroche, J., Hausfater, P., Jouquan, J., Kaplanski, G., Keshtmand, H., Khellaf, M., Lambotte, O., Launay, D., Levesque, H., Lidove, O., Liozon, E., Kim, L., Mahevas, M., Mariampillai, K., Mariette, X., Mathian, A., Mazodier, K., Michel, M., Morel, N., Mouthon, L., Ngack, R., Ninet, J., Oksenhendler, E., Pellegrin, J.-L., Peyr, O., Piette, A.-M., Poindron, V., Roux, F., Saadoun, D., Sahali, S., Saint-Marcoux, B., Sarrot-Reynauld, F., Schoindre, Y., Sellam, J., Sene, D., Serratrice, J., Seve, P., Sibilia, J., Simon, C., Sordet, C., Terrier, B., Trad, S., Viallard, J.-F., Vidal, E., Wechsler, B., Weiller, P.-J., & Zahr, N.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 72
- Issue
- 11
- Pages
- 1786-1792
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2099430274
- Cited by
- 205
- References
- 4
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). https://app.cochat.ai/papers/10.1136/annrheumdis-2012-202322
- The paper
- Costedoat-Chalumeau, N., Galicier, L., Aumaître, O., Francès, C., Le Guern, V., Lioté, F., Smail, A., Limal, N., Perard, L., Desmurs-Clavel, H., Boutin, D. L. T. H., Asli, B., Kahn, J.-E., Pourrat, J., Sailler, L., Ackermann, F., Papo, T., Sacré, K., Fain, O., . . . Zahr, N. (2013). Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-202322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.